2016-02-08T11:22:12-06:00 2015-06-30 KPMG LLP 345 PARK AVE NEW YORK NY 10154 990 2014-07-01 231907729 JDRF INTERNATIONAL % GARY CURTO C/O JDRF INT JDRF 2127859500 26 BROADWAY 15TH FL NEW YORK NY 10004 MARK GREENE CFO 2127859500 2016-02-05 true D DUNCAN P01249521 2127589700 2014 2016-08-17 19:52:53Z DEREK RAPP 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 274001331 false X www.jdrf.org X 1970 PA Accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications. SEE SCHEDULE O 33 32 932 300000 7891 2516 210068935 198918214 0 0 8724630 5469902 1086957 1087541 219880522 205475657 98317342 72354198 0 0 75662068 74558032 339000 339000 24260271 41387310 38879888 215705720 186131118 4174802 19344539 207538339 184040608 163676967 128561111 43861372 55479497 X Accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications. SEE SCHEDULE O false false 72354198 72354198 DIRECT RESEARCH FUNDING - FOR THE FY15 PERIOD ENDING JUNE 30, 2015, JDRF DIRECTLY FUNDED $72.4 MILLION IN RESEARCH GRANTS AND AGREEMENTS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O 19611575 RESEARCH SUPPORT - TO HELP DEFINE AND DIRECT ITS RESEARCH PROGRAMS AND TO FOSTER COLLABORATION WITH OTHERS INVOLVED WITH T1D RESEARCH, JDRF ORGANIZES SCIENTIFIC MEETINGS, SYMPOSIA, WORKSHOPS, AND CONFERENCES. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O 53281787 PUBLIC EDUCATION - JDRF EDUCATES THE PUBLIC ABOUT T1D AND ITS COMPLICATIONS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION, SEE SCHEDULE O 145247560 true true false true false false false false false true true true false false true true true false false true true true false true true true false true false true false false false false false false false true true false false false true true false false false true 457 5 true 932 true true true true IS NL DA false false false true true false false false true false X 33 32 false false false false false false false true true false true true true true true true true true true true true true AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X GARY CURTO CO JDRF INT 2124797551 26 BROADWAY 1TH FL NEW YORK NY 10004 STEVE HITCHINS FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 DIANE ADAMS FY13-15 BOARD MEMBER 3.0 0.0 X 0 0 0 SHANNON ALLEN FY13-15 BOARD MEMBER 3.0 0.0 X 0 0 0 DAVID REHR FY13-15 BOARD MEMBER 3.0 0.0 X 0 0 0 KAREN CASE FY14-16 TREASURER/CHAIR OF FINANCE 7.0 0.0 X X 0 0 0 TOM CHAPMAN FY14-16 SECRETARY/ CHAIR NOMINATING 7.0 0.0 X X 0 0 0 MATTHEW COHN FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 REBECCA DAVIES FY14-16 CHAIR,INTERNATIONAL AFFAIRS 5.0 0.0 X 0 0 0 MAARTEN DE GROOT FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 CAROL OXENREITER FY15-16 BOARD MEMBER 3.0 0.0 X 0 0 0 LORNE SHIFF FY14-16 BOARD MEMBER 7.0 0.0 X 0 0 0 NICOLE JOHNSON FY15-16 BOARD MEMBER 4.0 0.0 X 0 0 0 MIKE LEE FY15-16 CHAIR, COMPENSATION 7.0 0.0 X 0 0 0 PREETISH NIJHAWAN FY15-16 BOARD MEMBER 3.0 0.0 X 0 0 0 BILL PARSONS FY15-16 CHAIR, T1D VOICES COUNCIL 5.0 0.0 X 0 0 0 PAM SAGAN FY15-16 BOARD MEMBER 3.0 0.0 X 0 0 0 LARRY SOLER FY15-16 CHAIR, AUDIT 5.0 0.0 X 0 0 0 WENDY WOOD FY15-16 CHAIR, INVESTMENTS 5.0 0.0 X 0 0 0 PAM EDMONDS FY13-15 BOARD MEMBER 3.0 0.0 X 0 0 0 NANETTE DETURK FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 MICHELLE GRIFFIN FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 JOHN BRADY FY14-16 CHAIRMAN OF THE BOARD 20.0 0.0 X X 0 0 0 STEPHEN NEWMAN MD FY14-16 VICE CHAIRMAN OF THE BOARD 10.0 0.0 X X 0 0 0 TIMOTHY ST CLAIR FY14-16 BOARD MEMBER 3.0 0.0 X 0 0 0 LISA ALTMAN FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 GRANT BEARD FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 RANDY ANDERSON FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 TIMOTHY CLARK FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 MARK FISCHER-COLBRIE FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 SCOTT MCCORMICK FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 LISA REED FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 RED MAXWELL FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 DAVID REHR FY15-17 BOARD MEMBER 3.0 0.0 X 0 0 0 JEFFREY BREWER PRESIDENT AND CEO, ENDED 7/14 50.0 0.0 X 781372 0 17805 DEREK RAPP PRESIDENT AND CEO,STARTED 7/14 50.0 0.0 X 513847 0 23296 SANDRA HIJIKATA SVP US DEVELOPMENT 50.0 0.0 X 366322 0 1986 MARK GREENE CFO & ASST. TRES/ START 7/14 50.0 0.0 X 204167 0 8699 JILL CLARK VP.STRATEGIC INITIATIVES 50.0 0.0 X 219256 0 14139 JULIA GREENSTEIN VP RESEARCH 50.0 0.0 X 289410 0 18544 DAVID WHEADON EVP RESEARCH, ENDED 11/14 50.0 0.0 X 561478 0 19740 AARON KOWALSKI CHIEF MISSION OFFICER 50.0 0.0 X 317189 0 37793 RICHARD INSEL CHIEF SCIENTIFIC OFFICER 50.0 0.0 X 600469 0 39592 MARGO LUCERO SVP CORPORATE DEVELOPMENT 50.0 0.0 X 288033 0 39592 EDWARD J SEBALD CFO & ASST. TRES, ENDED 6/14 50.0 0.0 X 399418 0 19746 GERRI BOSTICK CHIEF HR OFFICER / ENDED 6/14 50.0 0.0 X 287869 0 18544 JAMES SZMAK VP DEVELOPMENT, ENDED 3/14 0.0 0.0 X 259360 0 19758 5088190 0 279234 157 true true false LW ROBBINS 201 SUMMER STREET HOLLISTON MA 01746 FUNDRAISING CONSULT 415770 BLACKBAUD 2000 DANIEL ISLAND DRIVE CHARLESTON SC 29492 FUNDRAISING SYSTEMS 2125882 HICKORY PRINTING SOLUTIONSLLC PO Box 69 HICKORY NC 28603 PRINTING CONSULTANT 603671 GSW WORLDWIDE 1180 AVE OF THE AMERICAS NEW YORK NY 10036 AD CONSULTANT 412017 SIX DEGREES MEDICAL 175 BLOOR ST TORONTO 0 CA PUBLIC ED CONSULTANT 1614479 109 4444391 124120228 70353595 15314210 198918214 0 995468 7891 987577 0 0 0 0 0 46292091 41817657 4474434 4474434 4474434 26527412 124120228 26527412 0 1012000 180605 831395 831395 0 MISCELLANEOUS PROGRAM REVENUE 900099 256146 256146 256146 205475657 7891 6549552 45419058 45419058 0 26935140 26935140 0 2824881 1663589 763108 398184 0 56269951 36251655 7616539 12401757 1709100 1096559 242350 370191 9310070 5973341 1320168 2016561 4444030 2851290 630163 962577 5006204 3214596 449895 1341713 565244 442303 48894 74047 242000 189365 20933 31702 409088 320111 35386 53591 339000 339000 566508 566508 0 2648828 2072708 229124 346996 1437364 1124737 124332 188295 3887001 3041578 336226 509197 0 10575478 4579369 2825777 3170332 2454000 1920255 212271 321474 0 2438000 1907735 210887 319378 0 0 4259001 3332668 368404 557929 537001 420203 46451 70347 OUTREACH EXPENSES 1613065 1262223 139530 211312 DUES & FEES 1531934 1198739 132512 200683 OTHER MISC EXPENSES 709172 30338 303829 375005 186131118 145247560 16623287 24260271 X 2846022 1020238 166431 1659353 1871397 8000321 14556180 29714230 31697456 28204025 12611584 11684316 0 0 0 0 0 0 0 0 3507142 3783235 29183325 12709391 18812540 16473934 59891458 33715865 61437447 49699118 2650935 2487658 0 0 502200 277906 207538339 184040608 17125273 13891579 137384458 105160199 6755269 6691858 0 0 0 0 0 0 0 0 0 0 2411967 2817475 163676967 128561111 X 1740091 17142205 35034733 31263491 7086548 7073801 43861372 55479497 207538339 184040608 19344539 -7726414 X false true X true false X 198202755 195105087 196010663 210068935 198918214 998305654 0 0 198202755 195105087 196010663 210068935 198918214 998305654 2322734 995982920 3183733 2070575 2055756 1660898 995468 9966430 0 35418 29449 6810 2516 74193 295028 117723 74636 136667 256146 880200 1009226477 0.98688 0.98654 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false 1000000 1000000 1500000 162802 162802 250000 250000 375000 17263 17263 true true false true 9699 true 3722 true 1058 true 347327 true 142376 false 504182 false JDRF LOBBYING ACTIVITIES FORM 990- SCH-C- GENERAL STATEMENT OF ACTIVITIES JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with T1D, the goal of JDRF is to create a world without T1D. Through research and advocacy, JDRF is accelerating progress on the most promising opportunities to cure, treat, and prevent T1D. JDRF's advocacy includes lobbying activity to ensure Congress continues to invest in critically important medical research and puts in place policies to advance the discovery, development, and delivery of better therapies for T1D. JDRF staff and volunteers communicate with government officials through email, phone calls, and meetings, to educate them on issues and encourage the advancement of legislation. 7935880 329000 8264880 6908880 1136000 109000 7935880 6898880 100000 81000 171000 6908880 5806880 1227000 350000 485000 6898880 5413880 526000 133000 5806880 0.13600 0.85590 0.00810 false false 4677038 2132319 2544719 24506287 10577072 13919215 16473934 HEDGE FUNDS 28574750 F US-NON-PUBLIC INVESTMENT FUNDS 21124368 F 49699118 0 SPLIT INTEREST CHRT RMDR TRUST 2817475 2817475 X 197182735 -7726414 -7726414 204909149 566508 566508 205475657 185564610 185564610 566508 566508 186131118 ORGANIZATION'S ENDOWMENT FUNDS FORM 990, PART X, LINE 28 & 29 THE INTENDED USE OF THE ORGANIZATION'S ENDOWMENT FUNDS IS TO USE THE FUNDS FOR BOTH SPECIFIC PROJECTS AS WELL AS SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. INCOME TAX POSITION OF JDRF INT. 990 SCH-D, PART X, LINE 2 JDRF is a not for profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is organized under the laws of the Commonwealth of Pennsylvania. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Income generated from activities unrelated to JDRF's exempt purpose is subject to tax under Internal Revenue Code Section 511. Unrelated Business Income Tax liability was insignificant for the years ending June 30, 2015 and 2014. true North America Grantmaking RESEARCH GRANTS 3986077 Central America and the Caribbean Investments 15553769 East Asia and the Pacific Grantmaking RESEARCH GRANTS 3843133 Europe (Including Iceland and Greenland) Grantmaking RESEARCH GRANTS 19344564 Europe (Including Iceland and Greenland) 1 1 Program Services 206383 1 1 1 1 42933926 42933926 East Asia and the Pacific 603016 CHECK/WIRE N/A N/A North America 110000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 90000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 623981 CHECK/WIRE N/A N/A Middle East and North Africa 251294 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1000784 CHECK/WIRE N/A N/A East Asia and the Pacific 560164 CHECK/WIRE N/A N/A East Asia and the Pacific 239882 CHECK/WIRE N/A N/A East Asia and the Pacific 90000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 164972 CHECK/WIRE N/A N/A East Asia and the Pacific 404761 CHECK/WIRE N/A N/A North America 337930 CHECK/WIRE N/A N/A North America 1253809 CHECK/WIRE N/A N/A North America 110000 CHECK/WIRE N/A N/A East Asia and the Pacific 144395 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1011084 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 418429 CHECK/WIRE N/A N/A North America 241010 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 711765 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 301648 CHECK/WIRE N/A N/A East Asia and the Pacific 246050 CHECK/WIRE N/A N/A North America 200000 CHECK/WIRE N/A N/A North America 296846 CHECK/WIRE N/A N/A North America 165000 CHECK/WIRE N/A N/A North America 94789 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 559502 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 183247 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1214304 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 199001 CHECK/WIRE N/A N/A East Asia and the Pacific 738421 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 334987 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 150000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 395635 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 314219 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 166067 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 755928 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1299775 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1089686 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 286175 CHECK/WIRE N/A N/A North America 616692 CHECK/WIRE N/A N/A East Asia and the Pacific ARTIFICIAL PANCREAS 250000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 343218 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 186993 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 175991 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 890445 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 200000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 99000 CHECL/WIRE N/A N/A Europe (Including Iceland and Greenland) 1006744 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 177750 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 55780 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 356423 CHECK/WIRE N/A N/A East Asia and the Pacific 413540 CHECK/WIRE N/A N/A Middle East and North Africa 280000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 165000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 448869 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 165000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 269473 CHECK/WIRE N/A N/A Middle East and North Africa IMMUNE THERAPIES 19998 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 218750 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 34816 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) PREVENTION 90787 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 100100 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 5231 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 100000 CHECK/WIRE N/A N/A North America REGENERATION 250000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) PREVENTION 284349 CHECK/WIRE N/A N/A North America BETA CELL THERAPIES 200000 CHECK/WIRE N/A N/A North America COMPLICATIONS 110000 CHECK/WIRE N/A N/A Middle East and North Africa REGENERATION 300000 CHECK/WIRE N/A N/A East Asia and the Pacific COMPLICATIONS 57904 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) REGENERATION 659974 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 110000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 356250 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) ARTIFICAL PANCREAS 1955131 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) REGENERATION 104003 CHECK/WIRE N/A N/A 62 13 true false true true false false GRANT MONITORING PROCEDURES SCH-F PART I LINE 2 Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution. X X X X X true LW ROBBINS MAIL PROCESSOR false 6000000 339000 5661000 Insurance Auto Auctions 2 Westbrook Corp Center Westchester IL 60154 CAR DONATION true 56725 31656 25069 6056725 370656 5686069 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY ILL WALK 4074040 390992 3683048 54671 16673 127989 ILL GALA 4239679 734389 3505290 62188 271340 307832 8 408 142333921 122994847 19339074 3499310 2873385 3754045 15559971 150647640 124120228 26527412 3561498 3199396 4078550 15687968 26527412 1012000 40000 140605 1012000 40000 140605 180605 831395 AL AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY true false false false 1.00000 GARY CURTO 26 BROADWAY-14TH FLOOR NEW YORK NY 10004 false GARY CURTO TAX MANAGER -JDRF 0 FILING GAMING APPLICATIONS AND REPORTS X true 831395 SCHEDULE G, PART I, LINE 2 INSURANCE AUTO AUCTIONS LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. THE PROGRAM RAISED $56,725 WITH TOTAL EXPENSES OF $31,656. A NET CHECK IS PAID DIRECTLY TO JDRF COVERING ALL EXPENSES AND FEES. TOTAL NET REVENUE FOR FY15 WAS $25,069. INSURANCE AUTO AUCTIONS IS LOCATED AT 3755 OMEC CIRCLE, RANCHO CORDOVA, CA 95742 SCHEDULE G, PART 1, LINE 2 LW ROBBINS ACTS AS A PFR/FRC FOR THE FUNCTION THEY PERFORM FOR JDRF. THEY ARE A MAILING PROCESSOR WITH VARIOUS FUNCTIONS AS A FUNDRAISING CONSULTANT. THE AMOUNT PAID TO LW ROBBINS WAS $339,000 FOR FUNDRAISING CONSULTATION; THE BALANCE WAS FOR PRODUCTS AND SERVICES. LW ROBBINS IS LOCATED AT 201 SUMMER STREET, HOLLISTON, MA 01746 true BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 9TH AVE SEATTLE WA 98101 910653422 501(C)3 2465154 N/A N/A BLACK HILLS REGIONAL EYE INSTITUTE 2800 3RD ST RAPID CITY SD 57701 060646973 501(C)3 5120 N/A N/A BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02115 042774441 501(C)3 2239076 N/A N/A CHILDRENS HOSPITAL OF PHILADELPHIA 1930 BROAD STREET PHILADELPHIA PA 19104 135598093 501(C)3 57904 N/A N/A EAST BAY RETINA CONSULTANTS INC 3300 WEBSTER ST OAKLAND CA 94609 943209895 10654 N/A N/A EASTERN VIRGINIA MEDICAL SCHOOL 358 MOWBRAY ACH NORFOLK VA 23501 237053028 501(C)3 263200 N/A N/A ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 237025620 501(C)3 285640 N/A N/A AUSTIN RETINA ASSOCIATES 3807 SPICEWOOD SPRINGS RD AUSTIN TX 78705 742034080 74391 N/A N/A HARVARD MEDICAL SCHOOL 200 LONGWOOD AVE BOSTON MA 02115 042103580 501(C)3 1841017 N/A N/A INDIANA UNIVERSITY 620 UNION DR INDIANAPOLIS IN 46202 356018940 501(C)3 675245 N/A N/A BETH ISRAEL MEDICAL CENTER 1 BROOKLINE AVE BOSTON MA 92121 135564934 501(C)3 53248 N/A N/A JOSLIN DIABETES CENTER 1 JOSLIN PL BOSTON MA 02215 042203836 501(C)3 3294286 N/A N/A FOUNDATION FOR THE NATIONAL INST OF HEALTH 9650 ROCKVILLE PIKE BETHESDA MD 20814 271518433 501(C)3 100000 N/A N/A BETA CELL THERAPIES GEORGIA REGENTS RESEARCH INSTITUTE 1120 15TH STREET AUGUSTA GA 30912 452019860 501(C)3 55780 N/A N/A CALIFORNIA INST FOR BIOMEDICAL RESEARCH 11119 NTORRY PINES RD LAJOLLA CA 92037 956047739 501(C)3 680557 N/A N/A EMORY UNIVERSITY 69 JESSE HILL JR DRIVE ATLANTA GA 30322 580566256 501(C)3 449999 N/A N/A RETINA VITREOUS ASSOCIATES 610 SIERRA ROSE DR RENO NV 89144 953699305 26169 N/A N/A GEORGIA TECH RESEARCH CORP 505 TENTH STREET ATLANTA GA 30332 580603146 501(C)3 399999 N/A N/A STANFORD UNIVERSITY 300 PASTEUR DR PALA ALTO CA 94305 941156365 501(C)3 926786 N/A N/A ELMAN RETINA GROUP 9114 PHILADELPHIA ROAD BALTIMORE MD 21237 521803322 5393 N/A N/A CENTER FOR RETINA MACULA DISEASE 250 AVE K WINTER HAVEN FL 33880 593028408 60451 N/A N/A NATIONAL JEWISH HEALTH 601 EAST 18TH STREET DENVER CO 80206 742044647 501(C)3 144365 N/A N/A OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PORTLAND OR 97239 237083114 501(C)3 250000 N/A N/A BECKMAN RESEARCH INST OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)3 262956 N/A N/A THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 609 MARY ELLEN CHAPEL HILL NC 27599 440680117 501(C)3 170583 N/A N/A LEXICON PHARMACEUTICALS 8800 TECH FOREST PL THE WOODLANDS TX 77381 999999999 250000 N/A N/A UNIV OF COLORADO AT DENVER HEALTH SCI CENTER PO BOX 6511 DENVER CO 80045 846049811 501(C)3 1885354 N/A N/A UNIVERSITY OF FLORIDA 1600 SW ARCHER ROAD GAINESVILLE FL 32610 590974739 501(C)3 3526671 N/A N/A UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVE NORTH WORCESTER MA 01605 043167352 501(C)3 150000 N/A N/A UNIVERSITY OF MIAMI SCHOOL OF MEDICINE 1450 NW 10TH AVE MIAMI FL 33136 590624458 501(C)3 497385 N/A N/A UNIVERSITY OF VIRGINIA 104 MIDMONT LN CHARLOTTESVILLE VA 22902 416042488 501(C)3 284695 N/A N/A UNIVERSITY OF MICHIGAN 1331 EAST ANN STREET ANN ARBOR MI 48109 386006309 501(C)3 940572 N/A N/A MASSACHUSETTS EYE & EAR INFIRMARY 243 CHARLES STREET BOSTON MA 02114 042103591 501(C)3 12565 N/A N/A UNIVERSITY OF PITTSBURGH E 1140 STARZL PITTSBURGH PA 15261 113708851 501(C)3 359538 N/A N/A UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO 3333 CA ST SAN FRANCISCO CA 94122 956006143 501(C)3 4873069 N/A N/A UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK MADISON WI 53706 396006492 501(C)3 579186 N/A N/A UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)3 495078 N/A N/A VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DR NASHVILLE TN 37232 620476822 501(C)3 1222039 N/A N/A YALE UNIVERSITY 149 ELM STREET NEW HAVEN CT 06520 060646973 501(C)3 1525231 N/A N/A BAYLOR COLLEGE OF MEDICINE-RESEARCH INSTITUTE 3500 GASTON AVE DALLAS TX 75246 751921898 501(C)3 311276 N/A N/A THE BROAD INSTITUTE OF HARVARD & MIT 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)3 599776 N/A N/A DUKE UNIVERSITY 4321 MEDICAL PARK DR DURHAM NC 27704 560532129 501(C)3 562520 N/A N/A RETINA CONSULTANTS HOUSTON 6560 FANNIN ST HOUSTON TX 77030 742109903 7938 N/A N/A FLORIDA RETINA INST 1025 PRIMERA LAKE MARY FL 32746 592009089 7731 N/A N/A JAEB CENTER FOR HEALTH RESEARCH FND 15310 Amberly Drive TAMPA FL 33647 593187624 501(C)3 1617993 N/A N/A VIACYTE 3550 GENERAL ATOMICS SAN DIEGO CA 92121 999999999 1000000 N/A N/A UNIVERSITY OF ARIZONA 811 N Euclid Ave Tucson AZ 85724 113661893 501(C)3 779681 N/A N/A RETINA MACULA INSTITUTE 4201 TORRANCE TORRANCE CA 90503 200804641 25636 N/A N/A RETINA INSTITUTE OF HAWAII 1620 ALA MOANA BLVD HONOLULU HI 96815 990357157 12205 N/A N/A SOUTHEAST RETINA CENTER 3685 WHEELER ROAD AUGUSTA GA 30909 581594221 10040 N/A N/A TEXAS RETINA ASSOCIATES 9600 NC EXPRESSWAY DALLAS TX 75231 751362336 17465 N/A N/A UNIVERSITY OF ALABAMA COLLEGE DRIVE BIRMINGHAM AL 35294 636001138 501(C)3 979512 N/A N/A MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)3 1426678 N/A N/A NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 231352685 501(C)3 261761 N/A N/A DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 501(C)3 249155 N/A N/A BETA CELL THERAPIES SELECTRA BIOSCIENCE INC 480 ARSENAL STREET WATERTOWN MA 02472 999999999 200000 N/A N/A SPOKANE EYE CLINIC 427 S BERNARD ST SPOKANE WA 99204 452887234 10070 N/A N/A TANDEM DIABETES CARE INC 11065 ROSELLE SAN DIEGO CA 92121 204327508 600000 N/A N/A UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE CHICAGO IL 60637 362177139 501(C)3 140630 N/A N/A MOUNT SINAI SCHOOL OF MEDICINE 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)3 296846 N/A N/A RETINA RESEARCH CENTER 3705 MEDICAL PARKWAY AUSTIN TX 78705 711023026 20219 N/A N/A RETINAL CONSULTANTS OF ARIZONA 1101 MISSOURI AVE PHOENIX AZ 85014 860708606 9492 N/A N/A IMMUNE THERAPIES INSTITUTE-NOVARTIS INSTITUTE-GENOMICS 10675 JOHN HOPKINS DR SAN DIEGO CA 92121 223610512 3802427 N/A N/A ILLINOIS INSTITUTE OF TECHNOLOGY 3300 SOUTH FEDERAL STREET CHICAGO IL 60616 362170136 501(C)3 109916 N/A N/A SANFORD RESEARCH 2301 E 60TH ST NORTH SIOUX FALLS SD 57104 460450378 506400 N/A N/A UNIVERSITY OF MINNESOTA 80 SOUTH 8TH STREET MINNEAPOLIS MN 55455 416007513 501(C)3 939929 N/A N/A UNIVERSITY OF VERMONT 1000 UNIVERSITY WAY COLCHESTER VT 05446 030179440 501(C)3 165000 N/A N/A VITREO-RETINAL ASSOCIATES 3355 EAGLE PARK GRAND RAPIDS MI 49525 999999999 15003 N/A N/A ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 113617119 501(C)3 784022 N/A N/A THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)3 53665 N/A N/A MEDICAL CENTER OPHTHALMOLOGY 11900 CROWN POINT SAN ANTONIO TX 78240 742143569 7535 N/A N/A MICHIGAN EYE CARE 29877 TELEGRAPH ROAD SOUTHFIELD MI 48034 383160340 5090 N/A N/A RUTGERS THE STATE UNIVERSITY 175 UNIVERSITY AVE NEWARK NJ 07107 462354111 501(C)3 156740 N/A N/A IMMUNE THERAPIES UNIVERSITY OF OKLAHOMA 660 PARRINGTON OKLAHOMA CITY OK 73126 736017987 501(C)3 302384 N/A N/A THERMALIN DIABETES 10000 CEDAR AVE CLEVELAND OH 44106 180057439 199888 N/A N/A UNIVERSITY OF HOUSTON 4888 LOOP CENTRAL DR HOUSTON TX 77204 746001399 501(C)3 248416 N/A N/A UNIVERSITY OF WASHINGTON 1401 15TH AVE SEATTLE WA 98195 911486484 501(C)3 248603 N/A N/A VALLEY RETINA INSTITUTE 1309 RIDGE ROAD MCALLEN TX 78503 742768498 5090 N/A N/A WESTERN MICHIGAN UNIVERSITY 1903 W MICHIGAN ANE KALAMAZOO MI 49008 454135256 501(C)3 118769 N/A N/A UNIVERSITY OF ROCHESTER 500 JOESPH WILLSON BLVD ROCHESTER NY 14611 160743209 501(C)3 220000 N/A N/A CLEMSON UNIVERSITY 105 COLLINGS ST CLEMSON SC 29634 157600025 501(C)3 55000 N/A N/A PREVENTION DIABETOMICS 2345 AMBERBROOK HILLSBORO OR 97006 999999999 80000 N/A N/A PREVENTION MICHIGAN STATE UNIVERSITY 426 AUDITORIUM LANDSING MI 48901 386552713 501(C)3 305750 N/A N/A COMPLICATIONS OREGON STATE UNIVERSITY 308 KERR ROAD CORVALLIS OR 97331 611730890 501(C)3 42478 N/A N/A ARTIFICIAL PANCREAS SANFORD-BURNHAM MEDICAL 10901 NTORREY PINES RD LA JOLLA CA 92037 510197108 501(C)3 250000 N/A N/A COMPLICATIONS UNIVERSITY OF ILLINOIS 801 W RANNDOL MILL RD URBANA IL 61801 376006007 501(C)3 384997 N/A N/A ENCAPSULATED ISLETS THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02108 042312909 501(C)3 653875 N/A N/A COMPLICATIONS THOMAS JEFFERSON UNIVERSITY 125 S 9TH STREET PHILADELPHIA PA 19019 232829095 501(C)3 110000 N/A N/A ARTIFICAL PANCREAS TIDEPOOL 450 TOOWNSEND ST SAN FRANCISCO CA 94112 999999999 625000 N/A N/A ARTIFICAL PANCREAS MEDICAL COLLEGE OF WISCONSIN 8707 WATERTWN MILWAUKEE WI 53204 390806261 501(C)3 249952 N/A N/A PREVENTION RESEARCH FOUNDATION OF SUNY UNIV AT BUFFALO 102 FARBER HALL BUFFALO NY 14201 160865182 501(C)3 232503 N/A N/A GLUCOSE MODULATION WAVE 80 BIOSCIENCES 2325 THIRD STREET SAN FRANCISCO CA 94102 999999999 140000 N/A N/A PREVENTION UNIVERSITY OF UTAH 201 PRESIDENTS CR SALT LAKE CITY UT 84101 876000526 501(C)3 500000 N/A N/A GLUCOSE MODULATION WAYNE STATE UNIVERSITY 5700 CASS AVE DETROIT MI 48201 383555142 501(C)3 149979 N/A N/A ENCAPSULATED ISLETS 66 28 GRANT MONITORING PROCEDURES SCH-I PART I LINE 2 Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution. X X true true X X X X X true false false false false false false true false EDWARD J SEBALD CFO & ASST. TRES, ENDED 6/14 182089 0 139718 77611 15852 3894 419164 0 JEFFREY BREWER PRESIDENT AND CEO, ENDED 7/14 358247 0 270000 0 153125 0 15852 0 1953 0 799177 0 0 0 DEREK RAPP PRESIDENT AND CEO,STARTED 7/14 263847 0 200000 0 50000 0 0 0 23296 0 537143 0 0 0 JULIA GREENSTEIN VP RESEARCH 260255 0 29155 0 0 0 15852 0 2692 0 307954 0 0 0 DAVID WHEADON EVP RESEARCH, ENDED 11/14 431164 0 130314 0 0 0 15852 0 3888 0 581218 0 0 0 AARON KOWALSKI CHIEF MISSION OFFICER 239568 0 77621 0 0 0 15193 0 22600 0 354982 0 0 0 SANDRA HIJIKATA SVP US DEVELOPMENT 318296 0 48026 0 0 0 0 0 1986 0 368308 0 0 0 MARK GREENE CFO & ASST. TRES/ START 7/14 204167 0 0 0 0 0 0 0 8699 0 212866 0 0 0 RICHARD INSEL CHIEF SCIENTIFIC OFFICER 490402 0 60067 0 50000 0 15852 0 23740 0 640061 0 0 0 JILL CLARK VP.STRATEGIC INITIATIVES 206899 0 12357 0 0 0 11816 0 2323 0 233395 0 0 0 JAMES SZMAK VP DEVELOPMENT, ENDED 3/14 259360 0 0 0 0 0 15852 0 3906 0 279118 0 0 0 MARGO LUCERO SVP CORPORATE DEVELOPMENT 251265 0 36768 0 0 0 15852 0 23740 0 327625 0 0 0 GERRI BOSTICK CHIEF HR OFFICER / ENDED 6/14 258690 0 29179 0 0 0 15852 0 2692 0 306413 0 0 0 HOUSING ALLOWANCE SCHEDULE J PART I, LINE 1A Dr. Insel, highest compensated employee, received a housing allowance that was grossed up as per the terms of his employment agreement. For the 2014 calendar year, the housing allowance provided to Dr. Insel was $50,000; such amount was treated as taxable compensation and included in his Form W-2. This amount was also reported on Schedule J, Part II, Col. (B)(iii). OTHER REPORTABLE COMPENSATION SCHEDULE J PART II, COL (B)(iii) DEREK RAPP, RECEIVED RELOCATION EXPENSES FOR THE 2014 CALENDAR YEAR, THE ALLOWANCE PROVIDED TO MR. RAPP WAS $50,000; SUCH AMOUNT WAS TREATED AS TAXABLE COMPENSATION AND INCLUDED IN HIS FORM W-2. THIS AMOUNT WAS ALSO REPORTED ON SCHEDULE J, PART II, COL (B)(iii). NON-FIXED PAYMENTS FORM 990, SCHEDULE J, PART I, LINE 7 JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL. (B) (II). SEVERANCE PAYMENTS SCHEDULE J, PART I, LINE 4A JEFFREY BREWER RECEIVED A SEVERANCE PAYMENT OF $153,125 WHICH IS REPORTED ON SCHEDULE J, PART II COL. (B)(III) OTHER REPORTABLE COMPENSATION. MR. BREWER'S LAST DATE OF EMPLOYMENT WAS JULY 21, 2014. EDWARD SEBALD RECEIVED A SEVERANCE PAYMENT OF $77,611 WHICH IS REPORTED ON SCHEDULE J, PART II COL. (B)(III) OTHER REPORTABLE COMPENSATION. MR. SEBALD'S LAST DATE OF EMPLOYMENT WAS AUG 21, 2014. DDC ADVOCACY JOHN BRADY, PRIN & DIR. 120500 SEE PART V false BUSINESS TRANSACTIONS SCHEDULE L, PART IV, COLUMN C FOR JDRF BOARD MEMBER JOHN BRADY WHO IS LISTED IN PART IV, LINE 1, THE SUM IN COLUMN (C) WAS THE AMOUNT PAID BY JDRF TO DDC FOR ADVOCACY CONSULTING; MR. BRADY IS A PRINCIPAL OWNER & MEMBER OF THE DDC ADVOCACY BOARD OF DIRECTORS. X 5 140605 TICKET SALES X 267 3610000 NET PROCEEDS OF SALE X MISC AUCTION ITEMS DONATED 10000 11563605 THRIFT SHOP 1 false true true THIRD PARTY ASSISTANCE LINE 32B INSURANCE AUTO AUCTIONS LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND THEY ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, INSURANCE AUTO AUCTIONS HANDLES ALL IRS 1098-C REPORTING. INSURANCE AUTO AUCTIONS IS A LICENSED PROFESSIONAL FUNDRAISER AND IS LICENSED IN THE STATES THAT REQUIRE IT TO REGISTER. FOR THE PERIOD ENDING 6/30/15, THE CAR PROGRAM LLC RAISED $56,725 WITH TOTAL EXPENSES OF $31,656. A NET CHECK IS PAID DIRECTLY TO JDRF. JDRF DOES NOT PAY INSURANCE AUTO AUCTIONS ANY EXPENSES OR FEES DIRECTLY. TOTAL NET REVENUE FOR FY-15 WAS $25,069. NONCASH CONTRIBUTIONS FORM 990, SCHEDULE M, PAGE 1 TYPES OF PROPERTY AND THE AMOUNTS LISTED IN PART I LINES 6 & 9 ARE THE ACTUAL AMOUNT THAT DONORS HAVE DONATED FOR VEHICLES AND SECURITIES. LINE 25 COLUMN(b),IS AN ESTIMATE OF MISC ITEMS THAT ARE SOLD AT VARIOUS AUCTIONS & RAFFLES. ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 JDRF IS THE LEADING GLOBAL ORGANIZATION FOCUSED ON TYPE 1 DIABETES (T1D) RESEARCH. JDRF'S GOAL IS TO PROGRESSIVELY REMOVE THE IMPACT OF T1D FROM PEOPLE'S LIVES UNTIL WE ACHIEVE OUR VISION OF A WORLD WITHOUT T1D. JDRF COLLABORATES WITH A WIDE SPECTRUM OF PARTNERS AND IS THE ONLY ORGANIZATION WITH THE SCIENTIFIC RESOURCES, REGULATORY INFLUENCE AND A WORKING PLAN TO BRING LIFE-CHANGING THERAPIES FROM THE LAB TO THE T1D COMMUNITY. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($72,354,198) JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers in more than 100 locations throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit www.jdrf.org LINE 4B ($19,611,575) JDRF MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, POLICY AND GOVERNMENT RELATIONS PROFESSIONALS WITH CREDENTIALS INCLUDING PHDs, MDs, MBAs, MAs AND OTHERS, EACH OF WHOM PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND THE DEPLOYMENT OF RESEARCH FUNDS FROM JDRF AND OTHERS TO CREATE A WORLD WITHOUT TYPE ONE DIABETES. IN THEIR RESPECTIVE RESPONSIBILITIES, THESE PROFESSIONALS PERFORM THE FUNCTIONS OF IDENTIFYING, EVALUATING AND INFLUENCING GROUNDBREAKING RESEARCH BEING FUNDED BY JDRF, OTHER FOUNDATIONS, GOVERNMENTS AND INDUSTRY TO ACHIEVE THE ORGANIZATION'S MISSION. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND THAT RESEARCH RESULTS ARE WELL UNDERSTOOD BY HEALTH CARE DECISION MAKERS. AS PART OFTHESE EFFORTS, JDRF ORGANIZES AND FUNDS SCIENTIFIC MEETINGS, SYMPOSIA, AND CONFERENCES WITH THE PURPOSE OF REVIEWING RESEARCH PROPOSALS, ENSURING THAT JDRF'S RESEARCH STRATEGY IS WELL-ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND TO ENABLE JDRF TO PROVIDE SCIENTIFIC UPDATES ON THE RESEARCH IT MANAGES. THIS WORK ALSO ENHANCES JDRF'S ABILITY TO FORECAST FUTURE SCIENTIFIC DIRECTION, TO JUDGE THE POTENTIAL EFFICIENCY AND EFFECTIVENESS OF NEW PATHWAYS AND TO IDENTIFY GAPS WHERE JDRF CAN FOCUS ITS FUNDING TO MAKE THE MOST IMPACT. JDRF'S LEADERSHIP IN THESE AREAS ENABLES IT TO DRIVE A STRATEGIC PLAN TO BRING ABOUT A CONTINUOUS FLOW OF LIFE-CHANGING THERAPIES AND ULTIMATELY, A CURE FOR T1D. LINE 4C ($53,281,787) Because of its leading role in diabetes research globally, JDRF is in a unique position to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people with the disease and their families, but also those at risk for developing the disease, and the general public. JDRF educates people about the warning signs of diabetes, which can be profoundly helpful in ensuring timely diagnoses and reducing the potential, short-term, catastrophic consequences of type 1 diabetes. JDRF also provides key information about current research directions and progress, and about human clinical trials in which people with the disease can participate (including via JDRF's Clinical Trials Connection service). JDRF chapters around the nation are committed to helping people identify and diagnose diabetes earlier and stay healthier so that they can benefit from a cure and treatments as they are developed. CONFLICT OF INTEREST POLICY FORM 990- PART VI-SECT B, LINE 12C ALL OFFICERS, DIRECTORS, KEY EMPLOYEES, BOARD AND COMMITTEE MEMBERS (BOTH CHAPTERS AND INTERNATIONAL BOARDS) ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY CONFLICTS. THE OFFICE OF THE PRESIDENT HANDLES THIS PROCESS AND JDRF'S INTERNAL AUDIT DEPARTMENT ANNUALLY AUDITS TO ENSURE COMPLIANCE. IF ANY CONFLICT DOES ARISE, THE BOARD MEMBERS WITH THE CONFLICTS WILL RECUSE THEMSELVES FROM THE MEETING AND/OR VOTE. PUBLIC DOCUMENTS FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS MAIN WEBSITE: www.jdrf.org. THE PUBLIC MAY ACCESS COPIES OF JDRF'S W-9, ANNUAL REPORT, 990 TAX RETURNS, 501(C)(3) IRS LETTER, & AUDITED FINANCIALS, AT THE FOLLOWING LINK: http://jdrf.org/about-jdrf/financials/ EXECUTIVE COMPENSATION POLICY PART VI, SECTION B, LINES 15a & 15b USING RELIABLE DATA AND INDEPENDENT EXTERNAL HUMAN RESOURCES CONSULTANTS, THE ORGANIZATION OBTAINS OBJECTIVE DATA ON COMPARABLE SALARIES AND BENEFITS FOR SIMILAR ORGANIZATIONS WITH LIKE KIND POSITIONS. THE COMPENSATION AND BENEFITS ARE REVIEWED BY AN AUTHORIZED BODY OR COMMITTEE COMPRISED OF MEMBERS OF THE BOARD OF DIRECTORS AND OTHERS WITH EXPERIENCE IN SETTING COMPENSATION POLICY WHO DETERMINE THAT THE COMPENSATION OF EXECUTIVES AND KEY PERSONNEL AND THE TREATMENT OF EMPLOYEES INVOLUNTARILY SEPARATED IS REASONABLE AND WITHIN ACCEPTABLE LIMITS. THE AUTHORIZED BODY OR COMMITTEE ADEQUATELY DOCUMENTS THE REVIEW OF JDRF EXECUTIVE COMPENSATION AND BENEFITS AND THE BASIS FOR ITS DETERMINATION, CONTEMPORANEOUSLY IN THE MINUTES OF THE COMPENSATION COMMITTEE. DURING THE TAX YEAR ENDED JUNE 30, 2015, JDRF'S COMPENSATION COMMITTEE MET ON DECEMBER 5, 2014 TO REVIEW SALARIES AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE. 990 REVIEW PROCESS FORM 990 SECTION B, PART VI, QUESTION 11B THE FIRST STEP IN THE FORM 990 REVIEW PROCESS BEGINS AT THE FINANCE LEVEL WITH THE ORGANIZATION'S TAX MANAGER WORKING WITH OUTSIDE TAX ADVISORS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE RETURN IS PREPARED AND CHECKED FOR ACCURACY. AFTER A DRAFT RETURN IS PREPARED, THE SECOND STEP IN THE REVIEW PROCESS INCLUDES A REVIEW OF THE DRAFT RETURN BY OUR TAX ADVISOR, ATTORNEY, DIRECTOR OF FINANCE AND CHIEF FINANCIAL OFFICER PRIOR TO AN AUDIT COMMITTEE REVIEW. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT FORM 990 ARE ADDRESSED AND MADE. THE THIRD STEP IN THE REVIEW PROCESS IS FOR THE JDRF AUDIT COMMITTEE TO REVIEW THE RETURN WITH OUR OUTSIDE TAX ADVISORS. ONCE THE RETURN IS APPROVED WITH ALL CHANGES AND READY TO FILE, IT IS PASSED ON TO THE BOARD. THE FOURTH AND FINAL STEP IN THE REVIEW PROCESS IS TO PROVIDE A FINAL COPY OF THE RETURN TO EACH VOTING MEMBER OF THE JDRF BOARD OF DIRECTORS BEFORE E-FILING THE FORM 990 WITH THE INTERNAL REVENUE SERVICE. DIABETES INVESTMENT FUND LLC C/O JDRF - 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 274967989 INVESTMENT DE JDRF CHARITABLE REMAINDER TRUST (5) ANNUITY PA false false false false false false false false false false false false false false false false false false false false